These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20224781)

  • 1. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology.
    Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA
    PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
    Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
    Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX.
    Askoxylakis V; Ehemann V; Rana S; Krämer S; Rahbari NN; Debus J; Haberkorn U
    Int J Mol Sci; 2012 Oct; 13(10):13030-48. PubMed ID: 23202936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel VHH nanobody against the active site (the CA domain) of tumor-associated, carbonic anhydrase isoform IX and its usefulness for cancer diagnosis.
    Araste F; Ebrahimizadeh W; Rasooli I; Rajabibazl M; Mousavi Gargari SL
    Biotechnol Lett; 2014 Jan; 36(1):21-8. PubMed ID: 24068505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of MN/CAIX in the diagnosis of renal cell carcinoma].
    Jiang YD; Ren F; Zheng SB
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):412-4. PubMed ID: 22445996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma.
    Leibovich BC; Sheinin Y; Lohse CM; Thompson RH; Cheville JC; Zavada J; Kwon ED
    J Clin Oncol; 2007 Oct; 25(30):4757-64. PubMed ID: 17947723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.
    Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP
    Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors].
    Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy.
    Bui MH; Seligson D; Han KR; Pantuck AJ; Dorey FJ; Huang Y; Horvath S; Leibovich BC; Chopra S; Liao SY; Stanbridge E; Lerman MI; Palotie A; Figlin RA; Belldegrun AS
    Clin Cancer Res; 2003 Feb; 9(2):802-11. PubMed ID: 12576453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain.
    Zatovicova M; Jelenska L; Hulikova A; Csaderova L; Ditte Z; Ditte P; Goliasova T; Pastorek J; Pastorekova S
    Curr Pharm Des; 2010; 16(29):3255-63. PubMed ID: 20819068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
    Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
    Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up.
    Zhang BY; Thompson RH; Lohse CM; Dronca RS; Cheville JC; Kwon ED; Leibovich BC
    BJU Int; 2013 Jun; 111(7):1046-53. PubMed ID: 23551810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.
    Chrastina A; Závada J; Parkkila S; Kaluz S; Kaluzová M; Rajcáni J; Pastorek J; Pastoreková S
    Int J Cancer; 2003 Jul; 105(6):873-81. PubMed ID: 12767076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
    Choueiri TK; Cheng S; Qu AQ; Pastorek J; Atkins MB; Signoretti S
    Urol Oncol; 2013 Nov; 31(8):1788-93. PubMed ID: 23141780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of a novel peptide ligand targeting human carbonic anhydrase IX.
    Rana S; Nissen F; Marr A; Markert A; Altmann A; Mier W; Debus J; Haberkorn U; Askoxylakis V
    PLoS One; 2012; 7(5):e38279. PubMed ID: 22693612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
    Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody G250 targeting CA Ⅸ: Binding specificity, internalization and therapeutic effects in a non-renal cancer model.
    Zatovicova M; Jelenska L; Hulikova A; Ditte P; Ditte Z; Csaderova L; Svastova E; Schmalix W; Boettger V; Bevan P; Pastorek J; Pastorekova S
    Int J Oncol; 2014 Dec; 45(6):2455-67. PubMed ID: 25230982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new peptide ligand for targeting human carbonic anhydrase IX, identified through the phage display technology.
    Askoxylakis V; Garcia-Boy R; Rana S; Krämer S; Hebling U; Mier W; Altmann A; Markert A; Debus J; Haberkorn U
    PLoS One; 2010 Dec; 5(12):e15962. PubMed ID: 21209841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX.
    Zat'ovicová M; Tarábková K; Svastová E; Gibadulinová A; Mucha V; Jakubícková L; Biesová Z; Rafajová M; Ortova Gut M; Parkkila S; Parkkila AK; Waheed A; Sly WS; Horak I; Pastorek J; Pastoreková S
    J Immunol Methods; 2003 Nov; 282(1-2):117-34. PubMed ID: 14604546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.